As was observed with AML, the BRD9 degraders, QA-68 and dBRD9-A, showed higher potency against the B- ALL lines than the BRD9 inhibitor, EA-89 (Supplementary Fig. 5E, F, Supplementary Fig. 6A–D). This evidence concerns the gene BRD9 and acute lymphoblastic leukemia.